Previous 10 | Next 10 |
Update 10:53am: Adds analyst comment, updates shares. Natera Inc. (NASDAQ:NTRA) dropped 30% after Hindenburg Research released a new short report on the prenatal testing company. Hindenburg alleges that Natera's revenue growth has been "fueled by deceptive sales and billing practice...
Gainers: Sunshine Biopharma (NASDAQ:SBFM) +159%. Cano Health (NYSE:CANO) +34%. Celyad Oncology (NASDAQ:CYAD) +24%. Mainz Biomed (NASDAQ:MYNZ) +21%. Bright Health Group (NYSE:BHG) +17%. Losers: Ontrak (NASDAQ:OTRK) -20%. Invacare (NYSE:IVC) -19%. Na...
Yext (NYSE:YEXT) -32% on Q4 results. Cricut (NASDAQ:CRCT) -30% on Q4 results. Stitch Fix (NASDAQ:SFIX) -22% on Q2 results. Ontrak (NASDAQ:OTRK) -22% on Q4 results. Nine Energy Service (NYSE:NINE) -17%. Hycroft Mining (NASDAQ:HYMC) -16%. PolyMet Mining (...
Natera Inc. (NASDAQ:NTRA) dropped 15% in premarket trading after Hindenburg Research released a new short report on the prenatal testing company Hindenburg alleges that Natera's revenue growth has been "fueled by deceptive sales and billing practices." The short report notes the com...
Natera, Inc. (NTRA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Michael Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - General Manager of Oncology & Transplant Conference Call Participants Tejas Savant -...
The following slide deck was published by Natera, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Natera, Inc. 2021 Q4 - Results - Earnings Call Presentation
Natera press release (NASDAQ:NTRA): Q4 GAAP EPS of -$1.48 misses by $0.18. Revenue of $173M (+53.9% Y/Y) beats by $4.19M. Outlook: Natera anticipates 2022 total revenue of $770 million to $790 million. Q1 Consensus Revenue Estimate $172.85M; 2022 Consensus Revenue Estimate $761.54M. 2022...
Natera Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire AUSTIN, Texas , Feb. 24, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and ye...
Natera Announces Fourth Quarter and Fiscal 2021 Earnings Conference Call PR Newswire AUSTIN, Texas , Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for ...
Natera Announces Results of Large, Multi-Center Clinical Experience Study Showing Excellent Positive Predictive Value of the Prospera™ Kidney Test PR Newswire AUSTIN, Texas , Feb. 17, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...